Evid Based Med 18:28-29 doi:10.1136/eb-2012-100755
  • Therapeutics
  • Systematic review

Prophylactic dose fondaparinux for 6 weeks in superficial thrombophlebitis of the legs reduces the risk for symptomatic thromboembolic complications

  1. Stephen M Pastores2
  1. 1Department of Medicine, Weill Cornell Medical Center, New York, New York, USA
  2. 2Department of Anesthesiology and Critical Care Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
  1. Correspondence to: Dr Maria T DeSancho
    1305 York Avenue, 7th floor, New York, NY 10021, USA; mtd2002{at}

Commentary on:


Superficial thrombophlebitis (ST), an inflammatory-thrombotic disorder in a superficial vein, is relatively common and estimated to occur in 1 per 1000 persons.1 The classic symptoms include pain, oedema, erythema and occasionally a palpable cord in the area of the thrombosed vein. Risk factors for ST include surgery, pregnancy and puerperium, female hormones, malignancy, infection, varicose veins, autoimmune disorders and thrombophilia.2 ST is a risk factor for deep venous thrombosis (DVT); 12–44% of patients with ST develop a DVT.3 The treatment of ST is highly variable ranging from no treatment to treatments with non-steroidal anti-inflammatory drugs, …

Free Sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EBM.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article